Innoviva (INVA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.56
- Estimate
- $0.50
- Surprise
- +11.5%
- Revenue (period 2026-06-30)
- $119.6M
- Score at report (before → after)
- 6.5 → 6.5/10
Revenue source: xbrl.
How the report landed
Innoviva (INVA) beat the $0.50 estimate with diluted EPS of $0.56 — a large 11.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.5/10) to Hold at 6.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates INVA Strong Buy at 7.0/10.
3 of the last 4 quarters beat the estimate; this quarter's +11.5% surprise compares with a +7.8% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Strong earnings beat streak (3/4)
- High-quality business
What argues against it
- Cyclical risk: PE expanding 2.0x (earnings normalizing)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $21.07
- Entry target
- $21.07
- Price target
- $29.75
- Stop
- $19.93
- Upside to target
- +41.2%
- Reward-to-risk
- 7.6:1
Forward estimates sit below the trailing run-rate (9.5× forward vs 4.9× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
INVA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.52B
- P/E (fwd)
- 9.5
- P/E (ttm)
- 4.9
- 52-week range
- $16.52–$25.15
- Off 52-week high
- 16.2%
- RSI (14)
- 54
- Volume vs avg
- 0.75×
- Score today
- 7.0/10